Does Rallies show 13F holders for CRVO?

Yes. Rallies tracks hedge fund and 13F ownership data for CRVO, including fund names, share counts, latest tracked quarter, and position changes when available.

Is CRVO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CRVO. It does not provide personalized investment advice.

CRVO (CervoMed Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

CervoMed Inc. Common Stock (CRVO) is a publicly traded Healthcare sector company. As of May 21, 2026, CRVO trades at $3.24 with a market cap of $28.15M and a P/E ratio of -1.08. CRVO moved +12.80% today. Year to date, CRVO is -58.51%; over the trailing twelve months it is -63.10%. Its 52-week range spans $1.80 to $16.94. Analyst consensus is strong buy with an average price target of $20.80. Rallies surfaces CRVO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns CRVO stock?

Hedge funds tracked by Rallies that own CRVO include Renaissance Technologies and Citadel Advisors. The latest tracked quarter is Sep 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for CervoMed Inc. Common Stock.

CRVO Key Metrics

Key financial metrics for CRVO
Metric	Value
Price	$3.24
Market Cap	$28.15M
P/E Ratio	-1.08
EPS	$-2.98
Dividend Yield	0.00%
52-Week High	$16.94
52-Week Low	$1.80
Volume	0
Avg Volume	0
Revenue (TTM)	$4.01M
Net Income	$-26.97M
Gross Margin	0.00%

Top Hedge Funds Holding CRVO

Renaissance Technologies holds 47.93K shares of CRVO, changed +48.25% as of Sep 30, 2024.
Citadel Advisors holds 10.81K shares of CRVO, changed -13.46% as of Dec 31, 2024.

Latest CRVO News

CervoMed’s Neflamapimod Yields 1.11-Point CDR-SB Benefit in DLB Patients — Mar 19, 2026
CervoMed’s Neflamapimod Joins UK EXPERTS-ALS Trial with 35-80 Patient Cohorts — Feb 18, 2026

Recent CRVO Insider Trades

Winton Matthew bought 1.50K (~$11.93K) on Nov 18, 2025.
ELDER WILLIAM ROBERT bought 2.50K (~$20.80K) on Nov 18, 2025.
Winton Matthew bought 3.50K (~$29.50K) on Nov 17, 2025.

CRVO Analyst Consensus

5 analysts cover CRVO: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $20.80.

Common questions about CRVO

Who owns CRVO stock?: Hedge funds tracked by Rallies that own CRVO include Renaissance Technologies and Citadel Advisors. The latest tracked quarter is Sep 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for CervoMed Inc. Common Stock.
Does Rallies show 13F holders for CRVO?: Yes. Rallies tracks hedge fund and 13F ownership data for CRVO, including fund names, share counts, latest tracked quarter, and position changes when available.
Is CRVO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CRVO. It does not provide personalized investment advice.